Plaque-type psoriasis Plaque-type psoriasis Rhodomyrtone
Conditions
Interventions
Polysorbate 80, Propylene glycol (5%w/w), Acrylates/C10-30 alkyl acrylate crosspolymer (0.5%w/w), mineral oil (10%w/w), Triethanolamine (0.2%w/w), Phenoxyethanol (0.15%w/w), R. Tomentosa (1%w/w), Puri
Experimental Drug,Active Comparator Drug
Group 1,Group 2
Sponsors
Southern Regional Hospital of Tropical Dermatology Trang Province, Tang, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Ten human volunteers aged 18 or older, with a diagnosis of mild to moderate plaque-type psoriasis were eligible.
Exclusion criteria
Exclusion criteria: Exclusion criteria included an inability to provide informed consent, severe allergies such as indoor, outdoor, or seasonal allergies, as well as ongoing medical conditions like dermatological issues, inflammation, or desquamation caused by dryness. Additionally, pregnant or nursing individuals were excluded from participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity 2, 4, 6, and 8 weeks Psoriasis Area and Severity Index, a tool used to measure the severity and extent of psoriasis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety 0, 4, and 8 weeks Blood test | — |
Countries
Thailand
Contacts
Public ContactWorachet Anantrangsee
Southern Regional Hospital of Tropical Dermatology Trang Province, Tang, Thailand
Outcome results
None listed